KalVista Pharmaceuticals Recognizes HAE Day
– A Global Awareness Day for a Rare Life-Threatening Condition –
“Our sponsorship of the
“HAE is a rare genetic disorder that causes swelling to various parts of
the body, and can be fatal when the swelling affects the throat due to
the risk of suffocation,” explains Mr.
As part of the awareness initiatives HAEi introduces “Support Family Testing” tools on the organization’s campaign website www.haeday.org.
“As HAE is a hereditary disorder, it is very important to have other
family members tested. To help patients in this process we have
developed two documents for patients and one for physicians,” says Mr.
HAEi is a global organization dedicated to raising awareness of C1 inhibitor deficiencies as HAE patients have a defect in the gene that controls a blood protein called C1-inhibitor, and therefore the disorder is also commonly referred to as C1-inhibitor deficiency. HAEi is a non-profit international network of presently 61 national HAE patient organizations spread across the globe.
“HAEi is established to promote co-operation, co-ordination and
information sharing between HAE specialists and national HAE patient
associations in order to help facilitate the availability of effective
diagnosis and management of C1 inhibitor deficiencies throughout the
world. Our purpose is to join the efforts and experience of the global
HAE community to achieve optimal standards of care and treatment for all
those patients affected by C1 inhibitor deficiencies,” says Mr.
The 2018 hae day :-) coincides with patients, relatives, caregivers, and
people from the industry walking part of the ancient pilgrimage
Jakobsweg route though
For more information, please visit www.kalvista.com.
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, available funding, our cash runway and future clinical trial timing and results. Further information on potential risk factors that could affect our business and its financial results are detailed in the annual report on Form 10-K filed on
KalVista Pharmaceuticals, Inc.
Leah Monteiro, 857-999-0808
Director, Corporate Communications & Investor Relations